- 询价
- MCE
- HY-L050
- 2026年03月25日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
【化合物数量】377
- 供应商：
广州市左克生物
蛋白泛素化（Protein ubiquitination）是指在泛素酶的催化作用下，给底物蛋白添加泛素分子的过程。蛋白泛素化主要包括泛素分子的激活、结合和连接三个步骤，分别由泛素激活酶E1、泛素结合酶 E2、泛素连接酶 E3 完成。主要过程如下：首先在ATP供能的情况下泛素激活酶E1粘附在泛素分子尾部的 Cys 残基上，激活泛素；接着，E1 酶将激活的泛素分子转移到E2泛素结合酶上，随后，E2 泛素结合酶和与底物结合的 E3 泛素连接酶结合，将泛素分子直接转移到底物蛋白上或通过 E3 泛素连接酶将泛素分子转移到底物蛋白上。蛋白泛素化是体内普遍存在的一种翻译后修饰，泛素化通过调节蛋白质的降解（通过蛋白酶体和溶酶体），改变蛋白质的细胞定位，影响蛋白质活性，促进或阻止蛋白质之间的相互作用，从而影响细胞凋亡、细胞周期、DNA 损伤修复、膜转运等细胞过程。泛素通路异常与神经退行性疾病、肿瘤、感染和免疫等多种疾病的发生有关。
MCE 提供 448 种可以用于泛素化研究的生物活性化合物。这些化合物靶向泛素化通路中的关键酶，是研究泛素化调控及相关疾病的有用工具。
我们将在明确您的产品用途后，向符合资质的客户通过定制合成服务的方式提供 MCE 泛素化化合物库，我们为该库中的所有产品提供溶液包装或粉末包装。溶液包装中，439 个产品以 10 mM 浓度提供，9 个产品以 2 mM 浓度提供。
溶液包装中，我们对于溶液状态稳定且溶解度不低于 10 mM 的产品，提供 10 mM 溶液；对于溶液状态稳定且溶解度介于 2~10 mM 的产品，我们提供 2 mM 溶液。
活性描述 & 特点
Biological Activity
• A unique collection of 448 bioactive ubiquitination related compounds for high throughput screening (HTS) and high content screening (HCS).
• Targets include proteasome, E1/E2/E3 Enzyme, deubiquitinase, p97, etc.
• A useful tool for the research of the regulation of ubiquitination and the corresponding diseases.
• Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
• Structurally diverse, medicinally active, and cell permeable.
• More detailed compound information with structure, IC50, and brief introduction.
• NMR and HPLC validated to ensure high purity and quality.
• All compounds are in stock and continuously updated.
产品详情
Product Details
Formulation:
A collection of 448 ubiquitination compounds supplied as pre-dissolved Solutions or Solid
Solution: 439 compounds supplied in 10 mM solution, 9 compounds supplied in 2 mM solution.
Layout:
96-well storage tube or 96-well plate: 1st and 12th column are left empty.
384-well plate: the first two columns and the last two columns are left empty.
Compounds with different concentrations or dissolved in different solvents will be put on separate plates. This way of layout may increase the number of plates because there could be three solvents and three concentrations.
If you have other requirements, please let us know.
Container:
96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
Storage:
-80°C
Shipping:
Blue ice or dry ice
化合物库组成
Composition
Ligands for E3 Ligase(154)
E1/E2/E3 Enzyme(120)
Apoptosis(86)
Deubiquitinase(78)
Proteasome(76)
MDM-2/p53(29)
Autophagy(28)
Molecular Glues(21)
p97(16)
NF-κB(14)
Bacterial(7)
Endogenous Metabolite(7)
NEDD8-activating Enzyme(7)
Reactive Oxygen Species (ROS)(7)
Akt(5)
Caspase(4)
Cathepsin(4)
Interleukin Related(4)
DNA/RNA Synthesis(3)
Fungal(3)
HIF/HIF Prolyl-Hydroxylase(3)
Keap1-Nrf2(3)
Parasite(3)
β-catenin(3)
AMPK(2)
Amyloid-β(2)
Bcl-2 Family(2)
Calcium Channel(2)
ClpP(2)
HIV(2)
IKK(2)
JAK(2)
Ligands for Target Protein for PROTAC(2)
Mitophagy(2)
MMP(2)
NOD-like Receptor (NLR)(2)
PINK1/Parkin(2)
PROTACs(2)
SARS-CoV(2)
5-HT Receptor(1)
Adrenergic Receptor(1)
Androgen Receptor(1)
Antibiotic(1)
Aryl Hydrocarbon Receptor(1)
Atg8/LC3(1)
ATGL(1)
Bcr-Abl(1)
c-Myc(1)
Carbonic Anhydrase(1)
Casein Kinase(1)
CDK(1)
Cytochrome P450(1)
DNA Methyltransferase(1)
Dopamine Receptor(1)
Drug Derivative(1)
EGFR(1)
Epigenetic Reader Domain(1)
ERK(1)
Factor Xa(1)
FLT3(1)
Histone Demethylase(1)
Histone Methyltransferase(1)
HMG-CoA Reductase (HMGCR)(1)
IAP(1)
IFNAR(1)
iGluR(1)
IKZF Family(1)
JNK(1)
mAChR(1)
Mitochondrial Metabolism(1)
mTOR(1)
MyD88(1)
Ornithine decarboxylase (ODC)(1)
Oxidative Phosphorylation(1)
p62(1)
PARP(1)
Phosphatase(1)
PI3K(1)
Pyroptosis(1)
Ribosomal S6 Kinase (RSK)(1)
SOD(1)
STAT(1)
TAM Receptor(1)
TNF Receptor(1)
TREM receptor(1)
Wnt(1)
γ-secretase(1)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验with this topic (1,2), but an update seemed necessary due to the rapid evolution of this field. The scope of this chapter is the management of different types of compound collec-tions from both physical and electronic points of view, including some aspects
Informatics in Compound Library Management
for compound library management, these systems do not come cheaply. Without doubt, for large pharma the return on investment for one of these systems can be justified; however, the upfront cost is typically prohibitive for smaller businesses looking to stretch
Compound Library Design for Target Families
and the extremely high-cost procedure jointly force the scientist to use additional computational tools for rational compound library design and selection. The present chapter will focus specifically on application of a predictive mapping computational technology
技术资料暂无技术资料 索取技术资料
